Adequin Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.38 M
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 11.63%
- Profit Growth 1.69%
- Ebitda 28.69%
- Net Worth 0.76%
- Total Assets 16.53%
About Adequin Pharmaceutical
Adequin Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 December 2020 (Four years and two months 10 days old ). Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.38 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Parida and Nayana Parida serve as directors at the Company.
Company Details
-
Location
Khorda, Odisha, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909OR2020PTC034988
-
Company No.
034988
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Dec 2020
-
Date of AGM
16 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Adequin Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Parida
|
Managing Director | 03-Dec-2020 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Nayana Parida
|
Director | 06-May-2022 | Current |
Financial Performance of Adequin Pharmaceutical.
Adequin Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.63% increase. The company also saw a slight improvement in profitability, with a 1.69% increase in profit. The company's net worth moved up by a moderate rise of 0.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adequin Pharmaceutical?
In 2023, Adequin Pharmaceutical had a public holding of 15.63%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Adequin Pharmaceutical?
Adequin Pharmaceutical has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adequin Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adequin Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
